Pretransplant tacrolimus dose requirements predict early posttransplant dose requirements in blood group AB0-incompatible kidney transplant recipients

Therapeutic Drug Monitoring

Volumn 38, Issue 2, 2016, Pages 217-222

  Shuker, Nauras ^a   De Man, Femke M ^a   De Weerd, Annelies E ^a   Van Agteren, Madelon ^a   Weimar, Willem ^a   Betjes, Michiel G H ^a   Van Gelder, Teun ^a   Hesselink, Dennis A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Dose requirement; Kidney transplantation; Tacrolimus

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; CREATININE; GLUCOCORTICOID; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RITUXIMAB; TACROLIMUS; BLOOD GROUP ANTIGEN;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIBODY TITER; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CONCENTRATION AT STEADY-STATE; DEMOGRAPHY; DIAGNOSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MONITORING; FEMALE; GRAFT RECIPIENT; HEADACHE; HEMATOCRIT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PERITONITIS; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; REHYDRATION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; GRAFT REJECTION; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADULT; AGED; BLOOD GROUP ANTIGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TACROLIMUS; TRANSPLANT RECIPIENTS; YOUNG ADULT;

EID: 84949034030     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000266     Document Type: Article

References (16)

1. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2:374-384.
2. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31:139-152.
3. Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006;112:184-198.
4. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993;54:205-218.
5. Boots JM, Christiaans MH, Undre NA, et al. Pretransplant pharmacoki-netics: does it predict the dose of tacrolimus after renal transplantation? Transpl Proc. 2002;34:3171-3172.
6. Campbell S, Hawley C, Irish A, et al. Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. Nephrology (Carl-ton). 2010;15:714-719.
7. Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol. 2003;56: 327-330.
8. van Agteren M, Weimar W, de Weerd AE, et al. The first fifty ABO blood group incompatible kidney transplantations: the Rotterdam experience. J Transplant. 2014;2014:913902.
9. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmaco-kinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-430.
10. de Jonge H, de Loor H, Verbeke K, et al. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther. 2012;92: 366-375.
11. Stifft F, Stolk LM, Undre N, et al. Lower variability in 24-Hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. Transplantation. 2013;97:775-780.
12. Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31:187-197.
13. Hesselink DA, Bouamar R, Elens L, et al. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014;53:123-139.
14. Passey C, Birnbaum AK, Brundage RC, et al. Dosing equation for ta-crolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72:948-957.
15. Armendariz Y, Garcia S, Lopez RM, et al. Hematocrit influences immu-noassay performance for the measurement of tacrolimus in whole blood. Ther Drug Monit. 2005;27:766-769.
16. Brown NW, Gonde CE, Adams JE, et al. Low hematocrit and serum albumin concentrations underlie the overestimation of tacrolimus concentrations by microparticle enzyme immunoassay versus liquid chromatography-tandem mass spectrometry. Clin Chem. 2005;51: 586-592.